Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14354040 | 1.00 | NR3C1 (0.50) | NR3C1ALDH1A1SMN1; SMN2POLBPTPN1 | |
| SCHEMBL15238695 | 0.73 | NR3C1 (0.56) | NR3C1ALDH1A1SMN1; SMN2POLBMEN1 | |
| SCHEMBL9779623 | 0.69 | HDAC3 (0.57) | ALDH1A1SMN1; SMN2POLBPTPN1MEN1 | |
| SCHEMBL9779620 | 0.69 | HDAC3 (0.57) | ALDH1A1SMN1; SMN2POLBPTPN1MEN1 | |
| SCHEMBL11705518 | 0.69 | CA1 (0.71) | ALDH1A1SMN1; SMN2POLBKMT2A | |
| SCHEMBL29522198 | 0.69 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1677059 | 0.69 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1884704 | 0.69 | MAPT (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1884705 | 0.69 | MAPT (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13719532 | 0.68 | ALDH1A1 (0.69) | NR3C1ALDH1A1SMN1; SMN2POLBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981122-B2 | Method for producing optically active N-monoalkyl-3-hydroxy-3-arylpropylamine compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20130005992-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE N-MONOALKYL-3-HYDROXY-3-ARYLPROPYLAMINE COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005992-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE N-MONOALKYL-3-HYDROXY-3-ARYLPROPYLAMINE COMPOUND | AHR, NAT1, AANAT | NR3C1 2102/4885ALDH1A1 248/4885SMN1; SMN2 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.